MX2019002976A - Formulaciones que contienen acetaminofén y sulfoalquil éter ciclodextrina. - Google Patents

Formulaciones que contienen acetaminofén y sulfoalquil éter ciclodextrina.

Info

Publication number
MX2019002976A
MX2019002976A MX2019002976A MX2019002976A MX2019002976A MX 2019002976 A MX2019002976 A MX 2019002976A MX 2019002976 A MX2019002976 A MX 2019002976A MX 2019002976 A MX2019002976 A MX 2019002976A MX 2019002976 A MX2019002976 A MX 2019002976A
Authority
MX
Mexico
Prior art keywords
sulfoalkyl ether
ether cyclodextrin
formulations containing
acetaminophen
containing acetaminophen
Prior art date
Application number
MX2019002976A
Other languages
English (en)
Spanish (es)
Inventor
Rajewski Roger
D Pipkin James
L Mosher Gerold
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of MX2019002976A publication Critical patent/MX2019002976A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
MX2019002976A 2016-09-16 2017-09-15 Formulaciones que contienen acetaminofén y sulfoalquil éter ciclodextrina. MX2019002976A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395794P 2016-09-16 2016-09-16
PCT/US2017/051919 WO2018053358A1 (en) 2016-09-16 2017-09-15 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin

Publications (1)

Publication Number Publication Date
MX2019002976A true MX2019002976A (es) 2019-07-10

Family

ID=61619250

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002976A MX2019002976A (es) 2016-09-16 2017-09-15 Formulaciones que contienen acetaminofén y sulfoalquil éter ciclodextrina.
MX2023003761A MX2023003761A (es) 2016-09-16 2019-03-14 Formulaciones que contienen acetaminofen y sulfoalquil eter ciclodextrina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023003761A MX2023003761A (es) 2016-09-16 2019-03-14 Formulaciones que contienen acetaminofen y sulfoalquil eter ciclodextrina.

Country Status (9)

Country Link
US (1) US20190255000A1 (enExample)
EP (1) EP3512511A4 (enExample)
JP (3) JP7181185B2 (enExample)
KR (2) KR20240005122A (enExample)
CN (2) CN110167543A (enExample)
AU (3) AU2017326519B2 (enExample)
CA (1) CA3036989A1 (enExample)
MX (2) MX2019002976A (enExample)
WO (1) WO2018053358A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119233815A (zh) * 2022-05-20 2024-12-31 株式会社大赛璐 液态医药组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20110015273A1 (en) * 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
SI2277546T1 (sl) * 2009-07-23 2015-09-30 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stabilen pripravljen za uporabo injekcijski sestavek paracetamola
AU2011302293B2 (en) * 2010-09-13 2015-11-26 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
KR20160033795A (ko) * 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
CN102871994B (zh) * 2012-09-29 2015-07-29 中国科学院大连化学物理研究所 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
BR102014005885B1 (pt) * 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
SMT202100404T1 (it) * 2016-02-04 2021-09-14 Czap Research And Development Llc Veicoli di complessi di inclusione di ciclodestrine stratificati e rilascio controllato

Also Published As

Publication number Publication date
WO2018053358A1 (en) 2018-03-22
EP3512511A1 (en) 2019-07-24
US20190255000A1 (en) 2019-08-22
KR20190065296A (ko) 2019-06-11
CN110167543A (zh) 2019-08-23
JP2024051102A (ja) 2024-04-10
AU2025204233A1 (en) 2025-06-26
JP2022140780A (ja) 2022-09-27
EP3512511A4 (en) 2020-05-20
JP2019532927A (ja) 2019-11-14
MX2023003761A (es) 2023-04-26
AU2023203660A1 (en) 2023-07-06
JP7181185B2 (ja) 2022-11-30
CN116869983A (zh) 2023-10-13
AU2017326519B2 (en) 2023-03-16
RU2019107764A3 (enExample) 2021-01-15
RU2019107764A (ru) 2020-10-16
CA3036989A1 (en) 2018-03-22
KR20240005122A (ko) 2024-01-11
AU2017326519A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
MY196173A (en) Cot Modulators And Methods Of Use Thereof
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MY188598A (en) Dexmedetomidine premix formulation
CA3011103A1 (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
MX2019008999A (es) Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo.
MX2017006148A (es) Composiciones para el cuidado personal con dos fases beneficas.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
PH12016500067A1 (en) Composition for promoting hair sprouting and hair growth
MX2025007184A (es) Triterpenoides sinteticos heteroaromaticos sustituidos polarmente en c17, y metodos de uso de los mismos
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX2023003761A (es) Formulaciones que contienen acetaminofen y sulfoalquil eter ciclodextrina.
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2023000348A (es) Composicion que contiene ciclodextrina y busulfan.
PH12015501538A1 (en) Topical ocular analgesic agents
BR112015020085A2 (pt) lipídeo que inibe a atividade do canal de nav1.9, composição, e kit
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
MX2016007956A (es) Pirrol carboxamidas fluorometil-sustituidas como bloqueadores del canal de calcio de cav2.2.